Venus Pharmagenerics Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 5.00 M
as on 09-12-2024
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 6.00 Cr
as on 09-12-2024
- Satisfied Charges ₹ 4.00 Cr
as on 09-12-2024
- Revenue 7.47%
(FY 2016)
- Profit 9.83%
(FY 2016)
- Ebitda 8.49%
(FY 2016)
- Net Worth 6.37%
(FY 2016)
- Total Assets 2.91%
(FY 2016)
About Venus Pharmagenerics
The Corporate was formerly known as Venus Medipack Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹6.00 Cr. The company has closed loans amounting to ₹4.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Phool Yadav and Ramdeo Ram serve as directors at the Company.
- CIN/LLPIN
U51909HP2008PTC031160
- Company No.
031160
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2008
- Date of AGM
28 Sep 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Venus Pharmagenerics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Phool Yadav  | Director | 16-Dec-2019 | Current |
| Ramdeo Ram | Director | 16-Dec-2019 | Current |
Financial Performance of Venus Pharmagenerics.
Venus Pharmagenerics Private Limited, for the financial year ended 2016, experienced modest growth in revenue, with a 7.47% increase. The company also saw a slight improvement in profitability, with a 9.83% increase in profit. The company's net worth moved up by a moderate rise of 6.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venus Pharmagenerics?
In 2016, Venus Pharmagenerics had a promoter holding of 67.96% and a public holding of 32.04%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Concept Cartonz Private LimitedActive 19 years 4 monthsPhool Yadav and Ramdeo Ram are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 15 Mar 2013 | ₹6.00 Cr | Open |
Oriental Bank Of Commerce Creation Date: 15 Oct 2008 | ₹4.00 Cr | Satisfied |
How Many Employees Work at Venus Pharmagenerics?
Unlock and access historical data on people associated with Venus Pharmagenerics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venus Pharmagenerics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venus Pharmagenerics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
